Xarelto Reviewers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA staff who participated in the review of Johnson & Johnson/Bayer’s oral anticoagulant rivaroxaban for prevention of stroke and systemic embolism in patients with atrial fibrillation
Medical |
Martin Rose, M.D., JD (Efficacy); Preston Dunnmon, M.D. (Safety) |
Chemistry |
Pei-I Chu, Ph.D |
Clinical Pharmacology |
Sabarinath Sreehharan, Ph.D.; Tzu-Yun McDowell, Ph.D. |
Pharmacology/Toxicology |
Pat Harlow, Ph.D. |
Biostatistics |
John Lawrence, Ph.D. |
Cross Discipline Team Leader |
Aliza Thompson, M.D. |
Regulatory Project Manager |
Alison Blaus |